Tscan Therapeutics Stock Alpha and Beta Analysis
| TCRX Stock | USD 4.77 0.13 2.80% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Tscan Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Tscan Therapeutics over a specified time horizon. Remember, high Tscan Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Tscan Therapeutics' market risk premium analysis include:
Beta 2.39 | Alpha (0.52) | Risk 3.67 | Sharpe Ratio (0.03) | Expected Return (0.12) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Tscan |
Tscan Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Tscan Therapeutics market risk premium is the additional return an investor will receive from holding Tscan Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Tscan Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Tscan Therapeutics' performance over market.| α | -0.52 | β | 2.39 |
Tscan Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Tscan Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Tscan Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Tscan Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Tscan Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Tscan Therapeutics shares will generate the highest return on investment. By understating and applying Tscan Therapeutics stock market price indicators, traders can identify Tscan Therapeutics position entry and exit signals to maximize returns.
Tscan Therapeutics Return and Market Media
The median price of Tscan Therapeutics for the period between Mon, Sep 2, 2024 and Sun, Dec 1, 2024 is 5.29 with a coefficient of variation of 9.17. The daily time series for the period is distributed with a sample standard deviation of 0.48, arithmetic mean of 5.21, and mean deviation of 0.39. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Klencke Barbara of 5000 shares of Tscan Therapeutics at 5.29 subject to Rule 16b-3 | 09/23/2024 |
2 | TScan therapeutics director buys 26,450 in company stock | 09/24/2024 |
3 | TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer th Annual Meeting | 10/04/2024 |
4 | Disposition of 10000 shares by Lynx1 Capital Management Lp of Tscan Therapeutics at 2.5148 subject to Rule 16b-3 | 11/01/2024 |
5 | TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and... | 11/05/2024 |
6 | TScan Therapeutics Soars 7.6 percent Is Further Upside Left in the Stock | 11/07/2024 |
7 | TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 11/12/2024 |
8 | TScan Therapeutics SWOT analysis biotech stock poised for key catalysts | 11/14/2024 |
9 | Tscan therapeutics sees 4,113 stock purchase by Lynx1 capital | 11/19/2024 |
10 | TScan Therapeutics, Inc. Shares Bought by Brown Brothers Harriman Co. | 11/27/2024 |
About Tscan Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Tscan or other stocks. Alpha measures the amount that position in Tscan Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 7.76 | 6.94 | 6.51 | 9.02 | Net Debt To EBITDA | 3.43 | 0.57 | 0.51 | 0.49 |
Tscan Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Tscan Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tscan Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Tscan Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Tscan Therapeutics. Please utilize our Beneish M Score to check the likelihood of Tscan Therapeutics' management manipulating its earnings.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Tscan Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.